Advanced search
1 file | 523.20 KB

Variations in target volume definition and dose to normal tissue using anatomic versus biological imaging (18F-FDG-PET) in the treatment of bone metastases : results from a 3-arm randomized phase II trial

Dieter Berwouts (UGent) , Katrien De Wolf, Wilfried De Neve (UGent) , Ana Maria Luiza Olteanu (UGent) , Bieke Lambert (UGent) , Bruno Speleers (UGent) , Ingeborg Goethals (UGent) , Indira Madani (UGent) and Piet Ost (UGent)
Author
Organization
Abstract
Introduction: To report the impact on target volume delineation and dose to normal tissue using anatomic versus biological imaging (F-18-FDG-PET) for bone metastases. Methods: Patients with uncomplicated painful bone metastases were randomized (1:1:1) and blinded to receive either 8Gy in a single fraction with conventionally planned radiotherapy (ConvRT-8Gy) or 8Gy in a single fraction with dose-painting-by-numbers (DPBN) dose range between 6 and 10Gy) (DPBN-8Gy) or 16Gy in a single fraction with DPBN (dose range between 14 and 18Gy) (DPBN-16Gy). The primary endpoint was overall pain response at 1month. Volumes of the gross tumour volume (GTV) - both biological (GTV(PET)) and anatomical (GTV(CT)) -, planning target volume (PTV), dose to thenormal tissue and maximum standardized-uptake values (SUVMAX) were analysed (secondary endpoint). Results: Sixty-three percent of the GTV(CT) volume did not show F-18-FDG-uptake. On average, 20% of the GTV(PET) volume was outside GTV(CT). The volume of normal tissue receiving 4Gy, 6Gy and 8Gy was at least 3x, 6x and 13x smaller in DPBN-8Gy compared to ConvRT-8Gy and DPBN-16Gy (P<0.05). Conclusion: Positron emitting tomography-information potentially changes the target volume for bone metastases. DPBN between 6 and 10Gy significantly decreases dose to the normal tissue compared to conventional radiotherapy.
Keywords
bone metastasis, dose-painting-by-numbers, palliative treatment, stereotactic body radiotherapy, volume analysis, POSITRON-EMISSION-TOMOGRAPHY, CELL LUNG-CANCER, RADIATION-THERAPY, PALLIATIVE RADIOTHERAPY, SPINAL METASTASIS, STEREOTACTIC RADIOSURGERY, LOCAL-CONTROL, PAIN-CONTROL, CONSENSUS, SURVIVAL

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 523.20 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Berwouts, Dieter, Katrien De Wolf, Wilfried De Neve, Ana Maria Luiza Olteanu, Bieke Lambert, Bruno Speleers, Ingeborg Goethals, Indira Madani, and Piet Ost. 2017. “Variations in Target Volume Definition and Dose to Normal Tissue Using Anatomic Versus Biological Imaging (18F-FDG-PET) in the Treatment of Bone Metastases : Results from a 3-arm Randomized Phase II Trial.” Journal of Medical Imaging and Radiation Oncology 61 (1): 124–132.
APA
Berwouts, D., De Wolf, K., De Neve, W., Olteanu, A. M. L., Lambert, B., Speleers, B., Goethals, I., et al. (2017). Variations in target volume definition and dose to normal tissue using anatomic versus biological imaging (18F-FDG-PET) in the treatment of bone metastases : results from a 3-arm randomized phase II trial. JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 61(1), 124–132.
Vancouver
1.
Berwouts D, De Wolf K, De Neve W, Olteanu AML, Lambert B, Speleers B, et al. Variations in target volume definition and dose to normal tissue using anatomic versus biological imaging (18F-FDG-PET) in the treatment of bone metastases : results from a 3-arm randomized phase II trial. JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY. 2017;61(1):124–32.
MLA
Berwouts, Dieter, Katrien De Wolf, Wilfried De Neve, et al. “Variations in Target Volume Definition and Dose to Normal Tissue Using Anatomic Versus Biological Imaging (18F-FDG-PET) in the Treatment of Bone Metastases : Results from a 3-arm Randomized Phase II Trial.” JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY 61.1 (2017): 124–132. Print.
@article{8505251,
  abstract     = {Introduction: To report the impact on target volume delineation and dose to normal tissue using anatomic versus biological imaging (F-18-FDG-PET) for bone metastases. 
Methods: Patients with uncomplicated painful bone metastases were randomized (1:1:1) and blinded to receive either 8Gy in a single fraction with conventionally planned radiotherapy (ConvRT-8Gy) or 8Gy in a single fraction with dose-painting-by-numbers (DPBN) dose range between 6 and 10Gy) (DPBN-8Gy) or 16Gy in a single fraction with DPBN (dose range between 14 and 18Gy) (DPBN-16Gy). The primary endpoint was overall pain response at 1month. Volumes of the gross tumour volume (GTV) - both biological (GTV(PET)) and anatomical (GTV(CT)) -, planning target volume (PTV), dose to thenormal tissue and maximum standardized-uptake values (SUVMAX) were analysed (secondary endpoint). 
Results: Sixty-three percent of the GTV(CT) volume did not show F-18-FDG-uptake. On average, 20\% of the GTV(PET) volume was outside GTV(CT). The volume of normal tissue receiving 4Gy, 6Gy and 8Gy was at least 3x, 6x and 13x smaller in DPBN-8Gy compared to ConvRT-8Gy and DPBN-16Gy (P{\textlangle}0.05). 
Conclusion: Positron emitting tomography-information potentially changes the target volume for bone metastases. DPBN between 6 and 10Gy significantly decreases dose to the normal tissue compared to conventional radiotherapy.},
  author       = {Berwouts, Dieter and De Wolf, Katrien and De Neve, Wilfried and Olteanu, Ana Maria Luiza and Lambert, Bieke and Speleers, Bruno and Goethals, Ingeborg and Madani, Indira and Ost, Piet},
  issn         = {1754-9477},
  journal      = {JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY},
  keyword      = {bone metastasis,dose-painting-by-numbers,palliative treatment,stereotactic body radiotherapy,volume analysis,POSITRON-EMISSION-TOMOGRAPHY,CELL LUNG-CANCER,RADIATION-THERAPY,PALLIATIVE RADIOTHERAPY,SPINAL METASTASIS,STEREOTACTIC RADIOSURGERY,LOCAL-CONTROL,PAIN-CONTROL,CONSENSUS,SURVIVAL},
  language     = {eng},
  number       = {1},
  pages        = {124--132},
  title        = {Variations in target volume definition and dose to normal tissue using anatomic versus biological imaging (18F-FDG-PET) in the treatment of bone metastases : results from a 3-arm randomized phase II trial},
  url          = {http://dx.doi.org/10.1111/1754-9485.12507},
  volume       = {61},
  year         = {2017},
}

Altmetric
View in Altmetric
Web of Science
Times cited: